CADONOT: Comparing axillary dissection or not in breast cancer surgery.

ABSTRACT:

Introduction

Sentinel lymph node biopsy (SLNB) is the gold standard for the axillary evaluation of clinically node-negative early breast cancer. The ACOSOG Z0011 study demonstrated the safety of omitting axillary dissection for limited SLNB disease, with other trials confirming SLNB alone or with axillary radiotherapy (AR) as non-inferior.

Methods

We followed PRISMA guidelines and registered at PROSPERO. Using Medline, Embase, and Cochrane, we reviewed randomized controlled trials (2010-2024). Outcomes, including 5-, 8-, and 10-year OS, DFS, recurrence rates, and lymphedema, were analyzed with R software and assessed for bias (Cochrane RoB) and evidence quality (GRADE). The focus was ALND vs. SLNB, alone or with AR, in cT1-T3 BC with 1-2 metastatic SLNs.

Results

Thirt

SUBMITTER: Mattar A 

PROVIDER: S-EPMC12013327 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature